Moxivig (Moxifloxacin Hydrochloride)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug stops bacterial cell division, leading to rapid bacterial death and clearance of the infection.

The dosing regimen for Moxivig is determined by the prescribing clinician based on the specific infection, severity, and patient factors. The prescriber will specify the number of drops, frequency, and duration of therapy.

Safety data for ocular moxifloxacin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To request Moxivig, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Moxivig belongs to the fluoroquinolone class, offering broad‑spectrum activity against Gram‑positive and Gram‑negative ocular pathogens. Compared with older agents such as ciprofloxacin or ofloxacin, moxifloxacin provides enhanced potency, better corneal penetration, and a convenient dosing schedule, though choice depends on local resistance patterns and physician preference.

Store Moxivig at room temperature, below 25 °C, in its original container. Protect the solution from light and moisture, and keep the cap tightly closed when not in use to maintain sterility.

Moxivig is applied as eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops into the conjunctival sac. The eye should be closed gently for a few seconds to allow absorption.

Serious risks include severe allergic reactions (e.g., anaphylaxis), corneal ulceration or thinning, and rare systemic hypersensitivity such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience swelling, rash, worsening pain, vision changes, or any signs of severe ocular inflammation.

Moxivig should not be used by individuals with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation. It is also contraindicated in patients with active viral or fungal eye infections, as it does not treat these conditions.